论文部分内容阅读
[目的]:探讨尾型同源盒转录因子-2(CDX2)在结直肠腺癌组织中的表达及其与预后的关系。[方法 ]采用免疫组化SP法检测CDX2在68例结直肠腺癌组织、30例结直肠腺瘤及30例正常结直肠组织中的表达情况,了解CDX2与结直肠腺癌患者临床病理特征的关系,并对患者进行随访。[结果]CDX2在结直肠腺癌、结直肠腺瘤及正常结肠组织中阳性表达率分别为52.9%(36/68)、76.7%(23/30)、90.0%(27/30),CDX2在结直肠腺癌组织中阳性表达率明显低于结直肠腺瘤及正常结肠组织(P<0.05),CDX2阳性表达与患者肿瘤浸润深度、淋巴结转移相关(P<0.05),与患者性别、年龄、部位、形态及分化程度无相关性(P>0.05)。CDX2阳性表达患者和阴性表达患者术后5年累积生存率分别为66.7%和53.1%,CDX2阴性表达患者术后生存时间较阳性患者明显缩短(χ2=5.565,P=0.018)。[结论]CDX2在结直肠腺癌组织中低表达,可能与结直肠腺癌的发生、发展及预后相关,可作为结直肠腺癌的参考指标,对结直肠腺癌诊断和预后评估具有重要意义。
[Objective] To investigate the expression of tailed homeobox transcription factor-2 (CDX2) in colorectal adenocarcinoma and its relationship with prognosis. [Methods] The expression of CDX2 in 68 cases of colorectal adenocarcinoma, 30 cases of colorectal adenoma and 30 cases of normal colorectal tissue was detected by immunohistochemical SP method. The relationship between CDX2 and clinicopathological features of colorectal adenocarcinoma Relationship, and follow-up of patients. [Results] The positive rates of CDX2 expression in colorectal adenocarcinoma, colorectal adenoma and normal colon tissues were 52.9% (36/68), 76.7% (23/30) and 90.0% (27/30), respectively The positive expression rate of CDX2 in colorectal adenocarcinoma was significantly lower than that in colorectal adenoma and normal colorectal tissues (P <0.05). The positive expression of CDX2 correlated with the depth of tumor invasion and lymph node metastasis (P <0.05) Location, shape and degree of differentiation had no correlation (P> 0.05). The 5-year cumulative survival rates of CDX2 positive patients and negative patients were 66.7% and 53.1%, respectively. The postoperative survival time of CDX2 negative patients was significantly shorter than that of positive patients (χ2 = 5.565, P = 0.018). [Conclusion] The low expression of CDX2 in colorectal adenocarcinoma may be related to the occurrence, development and prognosis of colorectal adenocarcinoma and may be used as a reference index of colorectal adenocarcinoma, which is of great significance for the diagnosis and prognosis evaluation of colorectal adenocarcinoma .